Navigation Links
Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
Date:12/3/2007

- Screening Determines Efficacy and Safety of Combination Drug Therapies -

HOPKINTON, Mass., Dec. 3 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today launched drug combination services through Caliper Discovery Alliances & Services (CDAS). These new services will help researchers determine the efficacy of combination drug therapies and identify potentially harmful combinations before therapies enter clinical trials. Studies, performed in Caliper's anti-cancer cell proliferation panel, cellular cytokine/chemokine release assays or using in vivo efficacy models, will help identify synergistic responses of drug combinations and eliminate antagonistic mixtures of drugs.

Drug combination studies are increasingly valuable to pre-clinical pharmaceutical research. The simultaneous use of a variety of drugs is common today for the treatment of bacterial infections, HIV, hypertension and cancer. Drug combination testing is subsequently a growing trend in many areas including oncology. If a combination is synergistic, lower doses can be used to achieve the same or better efficacy, which can lead to lower toxicity and safer patient care.

"Drug combination studies using cancer cell lines create a relationship between in vitro screening and profiling, and in vivo animal models. This connection is critical as researchers strive to understand how drug combinations may react in humans," said Kevin Hrusovsky, President and CEO, Caliper Life Sciences. "The exact same cell lines used in the in vitro drug combination testing can be used to create in vivo tumor models to further assess efficacy using the IVIS imaging platform."

The CDAS drug combination studies combine the liquid-handling, automation and imaging elements of Caliper's business. Drug combination studies can show whether chemical entities improve the efficacy of existing standard care treatments, providing a possible catalyst to FDA approval and market adoption. Testing combinations in vitro and in vivo also ensures that new clinical compounds will not decrease the effectiveness of standard therapy, thereby avoiding potentially harmful consequences for human study subjects. Drug combination studies also allow clinicians to better optimize the doses used in clinical trials as well.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of leading-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit http://www.caliperLS.com.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Alfacell Corporation to Present at UBS Global Life Sciences Conference
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):